2020年11月27日 · Vascular endothelial growth factor (VEGF) family member VEGF-A (also named as VEGF) and its receptor VEGFR2 contribute to the pathogenesis of CNV. Choroidal...

针对近视性 cnv ，已经研制出多种有效的治疗措施，特别是抗 vegf 治疗，此综述对近视性 cnv 的发病机制、流行病学特点、自然病程及治疗进展予以回顾。

2024年6月6日 · 脉络膜新生血管（Choroidal neovascularisation, CNV）是病理性近视的常见并发症。一旦出现，大多数患有近视性CNV（myopic CNV, mCNV）的眼睛都会发展为黄斑萎缩，从而导致不可逆的视力丧失。

2015年7月2日 · The anti-VEGF regimens are more effective on improving visual acuity, reducing central fundus thickness and central retina thickness than the traditional modalities. These anti-VEGF agents thus hold the potential to become the first-line medicine for treatment of CNV secondary to pathologic myopia.

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended as the first-line treatment option for mCNV. Prompt treatment of active mCNV with intravitreal anti-VEGF therapy has been demonstrated to be effective in terms of visual outcome improvements reducing the occurrence of late-stage complications.

2021年7月28日 · 目前，玻璃体腔注射血管内皮生长因子（VEGF）抗体是临床治疗眼底新生血管性疾病的主要策略，但仍然存在药物随房水代谢过快、难以富集眼底病灶和单一治疗策略效果有限的难题。 因此，即便多次注射，临床实际响应率也仅为40%~60%。 撰文 | 张思玮. 来源 | 小柯生命. 眼底新生血管的形成是年龄相关性黄斑变性、糖尿病视网膜病变等多种眼底疾病发生过程中的重要环节，若得不到有效治疗将严重影响视功能，甚至导致视力的丧失，给患者的生活和工作带 …

2019年11月26日 · Intravitreal anti-VEGF therapy seems to be safe and effective for secondary CNV after choroidal rupture. Compared to exudative age-related macular degeneration fewer injections are needed to control the disease.

2025年3月12日 · Sozinibercept (OPT-302), is a novel biologic ‘trap’ molecule, comprised of immunoglobulin (Ig)-like domains 1 to 3 of the extracellular domain of human VEGFR-3 fused to the Fc fragment of human IgG1, which binds and sequesters both VEGF-C and VEGF-D, preventing these two ligands from activating VEGFR-2 and VEGFR-3. 28 When used in ...

2025年3月23日 · Three meta-analyses evaluated anti-VEGF agents, primarily utilizing studies assessing ranibizumab or bevacizumab [10, 13, 16]. None of the meta-analyses yielded significant results with respect to BCVA improvement or SRF resolution. Notably, all the reviews incorporated studies that defined the presence of CNV as an exclusion criterion.

Clustered regularly interspaced short palindromic repeats (CRISPR)-based genomic disruption of vascular endothelial growth factor A (Vegfa) with a single gRNA suppresses choroidal neovascularization (CNV) in preclinical studies, offering the ...